Auriga Reiterates a 'Buy' on Health Management (HMA); Flu Activity Down, Orthopedic Surgeries Up

Auriga reiterates a 'Buy' on Health Management (NYSE: HMA) price target of $12.00.

Auriga analyst says, "Flu activity is significantly below 1Q11 in HMA markets, which should impact volume growth rate in 1Q12. Channel checks indicate orthopedic surgeries are growing, while cardiac cases are flat in HMA markets. Unemployment rate and economic activity are improving which should lower bad debt levels as the year progresses and may drive EPS growth above projection. We are adjusting our revenue, margin and EPS in 1Q to reflect current trends. Our 1Q12 revenue remains virtually the same as we lower volume (flu) but increase surgical growth. Our new 1Q12 EPS is $0.24 (previous $0.25) as we adjusted our SWB, supplies and bad debt assumptions. We believe HMA's deployment of surgical robots in its facilities should continue to drive company's surgical market share, which combined with margin expansion opportunity at acquired facilities, capacity to do more transactions, and focus on costs should continue to drive earnings in 2012 and beyond -- all without an improvement in economy."

For an analyst ratings summary and ratings history on Health Management click here. For more ratings news on Health Management click here.

Shares of Health Management closed at $6.69 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
• Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'